CVS HEALTH Corp: Form 10-K for the period ended Dec 31, 2015
Filed with the SEC on Feb 9, 2016 and accepted by EDGAR at Feb 9, 2016, 16:29 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-10-01 to 2015-12-31 | $41.15bn | us-gaap:Revenues |
| Revenue | 12 months2015-01-01 to 2015-12-31 | $153.29bn | us-gaap:Revenues |
| Cost of revenue | 12 months2015-01-01 to 2015-12-31 | $126.76bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2015-10-01 to 2015-12-31 | $7.30bn | us-gaap:GrossProfit |
| Gross profit | 12 months2015-01-01 to 2015-12-31 | $26.53bn | us-gaap:GrossProfit |
| Operating income | 3 months2015-10-01 to 2015-12-31 | $2.73bn | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2015-01-01 to 2015-12-31 | $9.45bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2015-01-01 to 2015-12-31 | $859.0m | us-gaap:InterestExpense |
| Income tax | 12 months2015-01-01 to 2015-12-31 | $3.39bn | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months2015-10-01 to 2015-12-31 | $1.34 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2015-01-01 to 2015-12-31 | $4.63 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2015-10-01 to 2015-12-31 | $1.35 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2015-01-01 to 2015-12-31 | $4.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2015-01-01 to 2015-12-31 | 1,126,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2015-01-01 to 2015-12-31 | $8.41bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2015-01-01 to 2015-12-31 | $2.37bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2015-01-01 to 2015-12-31 | $1.58bn | us-gaap:PaymentsOfDividends |
| Share repurchases | 12 months2015-01-01 to 2015-12-31 | $5.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2015-12-31 | $2.46bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-12-31 | $30.38bn | us-gaap:AssetsCurrent |
| Total assets | At period end2015-12-31 | $93.66bn | us-gaap:Assets |
| Current liabilities | At period end2015-12-31 | $23.17bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2015-12-31 | $26.27bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2015-12-31 | $1.20bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2015-12-31 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2015-12-31 | $37.20bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000064803-16-000074. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.